Clarity Pharmaceuticals Ltd
ASX:CU6
Intrinsic Value
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. [ Read More ]
The intrinsic value of one CU6 stock under the Base Case scenario is 1.03 AUD. Compared to the current market price of 3.7 AUD, Clarity Pharmaceuticals Ltd is Overvalued by 72%.
Valuation Backtest
Clarity Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling CU6 stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Clarity Pharmaceuticals Ltd
| Current Assets | 57.6m |
| Cash & Short-Term Investments | 38m |
| Receivables | 15.4m |
| Other Current Assets | 4.2m |
| Non-Current Assets | 607.7k |
| PP&E | 594.7k |
| Other Non-Current Assets | 13k |
| Current Liabilities | 4.9m |
| Accounts Payable | 555.8k |
| Accrued Liabilities | 244k |
| Other Current Liabilities | 4.1m |
| Non-Current Liabilities | 217.7k |
| Other Non-Current Liabilities | 217.7k |
Earnings Waterfall
Clarity Pharmaceuticals Ltd
|
Revenue
|
11.8m
AUD
|
|
Operating Expenses
|
-44.5m
AUD
|
|
Operating Income
|
-32.7m
AUD
|
|
Other Expenses
|
2.2m
AUD
|
|
Net Income
|
-30.6m
AUD
|
Free Cash Flow Analysis
Clarity Pharmaceuticals Ltd
CU6 Profitability Score
Profitability Due Diligence
Clarity Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Clarity Pharmaceuticals Ltd's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
CU6 Solvency Score
Solvency Due Diligence
Clarity Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Clarity Pharmaceuticals Ltd's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CU6 Price Targets Summary
Clarity Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for CU6 is 3.47 AUD with a low forecast of 3.12 AUD and a high forecast of 4.2 AUD.
Shareholder Return
CU6 Price
Clarity Pharmaceuticals Ltd
| Average Annual Return | -9.12% |
| Standard Deviation of Annual Returns | 58.76% |
| Max Drawdown | -75% |
| Market Capitalization | 973.3m AUD |
| Shares Outstanding | 271 098 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Clarity Pharmaceuticals Ltd. engages in the development of radiopharmaceutical products focused on the treatment of serious diseases. The firm is focused on developing products to address the growing need for radiopharmaceuticals in oncology. Its has a diverse range of products in clinical trials which address both large indications such as prostate cancer and breast cancer, as well as rare and orphan indications such as neuroendocrine tumours (NETs) and neuroblastoma of cancer. The SAR Technology platform is the Company’s platform. Its pipeline of products in clinical and preclinical stages include SARTATE, SAR-Bombesin and SAR-bisPSMA. Its SARTATE is for the treatment of neuroblastoma, and for the diagnosis of NETs. Its SAR-Bombesin is a pan-cancer treatment product, including for the treatment of breast cancer and prostate cancer. Its SAR-bisPSMA is for the treatment of prostate cancer, and for the diagnosis of prostate cancer.
Contact
IPO
Employees
Officers
The intrinsic value of one CU6 stock under the Base Case scenario is 1.03 AUD.
Compared to the current market price of 3.7 AUD, Clarity Pharmaceuticals Ltd is Overvalued by 72%.
You don't have any saved screeners yet
